![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Cadila Healthcare Limited Ahmedabad In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Oxaliplatin, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2010-351 - Rev 00
This Chemical Type CEP, issued on February 28, 2012, remains in force until September 05, 2016, ensuring its reliability within the pharmaceutical industry.
Substance Number 2017 associated with this CEP further emphasizes